We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
BMK1 is involved in the regulation of p53 through disrupting the PML-MDM2 interaction.
- Authors
Yang, Q; Liao, L; Deng, X; Chen, R; Gray, N S; Yates, J R; Lee, J D
- Abstract
Promyelocytic leukemia protein (PML) modulates the p53 tumor suppressor through its interaction with p53 and MDM2. We found that activated big MAP kinase 1 (BMK1) preferentially associates with PML isoform IV and disrupts PML-MDM2 interaction. Doxorubicin, a common chemotherapeutic agent, is known to promote PML-mediated p53 activation in part by promoting PML-dependent MDM2 nucleolar sequestration. We discovered that BMK1 deactivation coupled with doxorubicin synergistically enhanced MDM2 nucleolar sequestration and, consequently, promoted PML-mediated p53 upregulation leading to tumor cell apoptosis in vitro and tumor regression in vivo. Collectively, these results not only suggest that BMK1 activity has a role in suppressing p53 by blocking the interaction between PML and MDM2, but also implicate that pharmacological BMK1 inhibitor should significantly enhance the anticancer capacity of doxorubicin-based chemotherapy.
- Subjects
MITOGEN-activated protein kinases; P53 antioncogene; MYELOID leukemia; UBIQUITIN ligases; PROTEIN-protein interactions; DOXORUBICIN; CANCER chemotherapy
- Publication
Oncogene, 2013, Vol 32, Issue 26, p3156
- ISSN
0950-9232
- Publication type
Article
- DOI
10.1038/onc.2012.332